PACAP-38
Fat LossEndogenous neuropeptide / researchExperimental
38-aa neuropeptide that activates PAC1/VPAC receptors. Research tool in migraine, neuroprotection, and metabolic models. Not FDA-approved as a drug.
For research use only.
Key Facts
- CAS
- 137061-48-4
- Molecular Weight (MW)
- ≈4534 g/mol
- Half-life
- Very short; rapidly degraded by peptidases
- Unit
- mcg
- Administration Route
- —
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- PAC1VPAC1VPAC2
Overview
38-aa neuropeptide that activates PAC1/VPAC receptors. Research tool in migraine, neuroprotection, and metabolic models. Not FDA-approved as a drug.
Protocol
- Dosage Range
- Per research protocol
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Science
Mechanism of Action
Gs-coupled PAC1/VPAC agonism raises cAMP in neurons and endocrine cells; PACAP-38 is also a migraine-triggering peptide in human challenge studies.
Targets
PAC1VPAC1VPAC2
Studies
- PACAP-38 migraine provocation— Journal/year not available
Benefits
Neuropeptide-receptor research
Potential Side Effects
- Flushing
- Headache / migraine provocation
References
- PMID 19193677External link · Year —